Biotech & life science

  • US Alzheimer’s drug pioneer Anavex presses-on, despite regulatory setback

    US Alzheimer’s drug pioneer Anavex presses-on, despite regulatory setback

    Alzheimer’s drug pioneer Anavex is pressing ahead with plans to secure approval for its ground-breaking treatment despite a recent setback. Earlier this year it lodged an appeal against the European Medicines Agency (EMA) decision to reject its application for drug approval in December 2025. But, Anavex has now withdrawn this appeal as it seeks to [...]

  • Special report: Can humankind really live forever?

    Special report: Can humankind really live forever?

    This month Agetech World is focusing on the future. What does healthy lifespan look like, and how long can it last? Our introductory article in this special series looks at the ‘biohacking’ quest to re-engineer ageing - and who it will benefit? Click below to read Agetech World editor Peter McCusker's report now.     [...]